Loading...
| A00501 | Pages: 210 | Sep 2021 | 2749 Views | | |
| Author(s) : Sushant Terdale , Onkar Sumant | Tables: 121 | Charts: 35 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Macular Edema And Macular Degeneration Market
Request Now !The global macular edema and macular degeneration market size was valued at $8,301 million in 2020, and is projected to reach $16,530 million by 2030, registering a CAGR of 7.3% from 2021 to 2030. Macular edema occurs when there is an abnormal leakage and accumulation of fluid in the macula from damaged blood vessels in the nearby retina, which leads to vision impairment and might lead to vision loss. Macular edema can be of two types, namely, cystoid macular edema and diabetic macular edema. In addition, macular degeneration is a painless disease condition that leads to loss of central vision, a condition due to the retinal damage, and majorly affects adults more than 50 years or geriatric population. Macular degeneration is of two types, namely, wet macular degeneration and dry macular degeneration. Rise in aging population has increasingly become an issue that leads to growing number of macular edema and degeneration case, which contributes the growth of the market. Therapies such as anti-vascular endothelial growth factor drugs for treatment of diabetic macular edema and Lucentis (ranibizymab) & Avastin drugs for macular degeneration play a significant role in growth of the global macular edema and macular degeneration market.
Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans.
Get more information on this report : Request Sample Pages
After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement.
Furthermore, the virus has high potential of lethality in geriatric population. On 11th March 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, there are only a few vaccines that received emergency approvals for COVID-19 treatment or prevention. Thus, social distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns.
Almost every nation is dealing with the outbreak. Most markets are experiencing a decline, owing to the outbreak. The COVID-19 pandemic is an unprecedented global public health challenge and is anticipated to have a negative impact on the macular edema and macular degeneration market. Macular edema and macular degeneration specialists prefer drug therapy and laser treatment for macular edema and macular degeneration treatment and surgery. The most commonly performed treatment was laser treatment procedure in macular edema and macular degeneration before the COVID-19 pandemic. Although laser treatment remains the most commonly performed established macular edema and macular degeneration treatment and surgery, which is being performed with reduced frequency during the COVID-19 pandemic due to decreasing number of postoperative visits and procedures required.
On the basis of treatment type, the market is segmented into drug therapy and laser treatment. The drug therapy segment accounted for the majority of market share of the global market in 2020. The factors such as increase in prevalence of diabetes patients who have diabetes for many years can develop neuropathy, a reduced or complete lack of vision due to nerve damage and surge in cases of diabetic macular edema (DME) drives the growth of the market.
By application, the market is segmented into macular edema (diabetic macular edema (DME) and cystoid macular edema (CME)) and macular degeneration (dry age-related macular degeneration and wet age-related macular degeneration). The macular degeneration segment accounted for the majority of market share in 2020, and is expected to remain dominant during the forecast period, owing to rise in occurrence of diabetes due to unhealthy lifestyle of people and increasing cases of diabetes. These are the factors that propel the market growth.
Get more information on this report : Request Sample Pages
By end user, the market is segmented into hospitals, clinics, and others. The hospital segment accounted for maximum market revenue in 2020, and is anticipated to maintain its dominant position during the forecast period. This is attributed to increase in cases of diabetes and treatment of macular edema and macular degeneration including drug therapy and laser treatment in hospitals.
Get more information on this report : Request Sample Pages
Region wise, the macular edema and macular degeneration market is analyzed across North America, Asia-Pacific, Europe, and LAMEA. North America dominated the market in 2020, accounting for the highest share and is anticipated to maintain this trend throughout the forecast period. This is attributed to the increasing case of diabetic macular edema (DME), cystoid macular edema (CME), dry age-related macular degeneration, and wet age-related macular degeneration, thus rise in demand for macular edema and macular degeneration treatment to treat macular edema and macular degeneration is a major factor that contributes toward growth of the macular edema and macular degeneration market. However, as per macular edema and macular degeneration market forecast, Europe is projected to register highest growth rate from 2021 to 2030.
Get more information on this report : Request Sample Pages
This report provides comprehensive competitive analysis and profiles of prominent market players such as F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc Allergan, Regeneron Pharmaceuticals Inc., Alimera Sciences, Bausch Health Companies Inc., Kubota Pharmaceutical Holdings Co., Bayer AG, and RegenX bio.
Key Benefits For Stakeholders
Key Market Segments
By Treatment Type
By Application
By End User
By Region
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in aging population
3.5.1.2.Advancements in treatment
3.5.2.Restraints
3.5.2.1.Dearth of skilled professionals
3.5.3.Opportunities
3.5.3.1.R&D investment by pharmaceutical
3.6.Covid-19 Impact analysis on the macular edema and macular degeneration market
CHAPTER 4:MACULAR EDEMA AND MACULAR DEGENERATION MARKET,
4.1.Overview
4.1.1.Market size and forecast, by treatment type
4.2.Drug Therapy
4.2.1.Key trends and growth opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Laser Treatment
4.3.1.Key trends and growth opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
CHAPTER 5:MACULAR EDEMA AND MACULAR DEGENERATIONMARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Macular Edema
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.2.2.1.Diabetic Macular Edema (DME)
5.2.2.2.Cystoid Macular Edema (CME)
5.3.Macular Degeneration
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.3.2.1.Dry age-related macular degeneration
5.3.2.2.Wet age-related macular degeneration
CHAPTER 6:MACULAR EDEMA AND MACULAR DEGENERATIONMARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Clinics
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Others
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
CHAPTER 7:MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast, by region
7.2.North America
7.2.1.Key trends and growth opportunities
7.2.2.Market size and forecast, by Treatment
7.2.3.Market size and forecast, by application
7.2.4.Market size and forecast, by end user
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.2.U.S. market size and forecast, by Treatment
7.2.5.3.U.S. market size and forecast, by application
7.2.5.4.U.S. market size and forecast, by end user
7.2.5.5.Canada
7.2.5.6.Canada market size and forecast, by Treatment
7.2.5.7.Canada market size and forecast, by application
7.2.5.8.Canada market size and forecast, by end user
7.2.5.9.Mexico
7.2.5.10.Mexico market size and forecast, by Treatment
7.2.5.11.Mexico market size and forecast, by application
7.2.5.12.Mexico market size and forecast, by end user
7.3.Europe
7.3.1.Key trends and growth opportunities
7.3.2.Market size and forecast, by Treatment
7.3.3.Market size and forecast, by application
7.3.4.Market size and forecast, by end user
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.2.Germany market size and forecast, by Treatment
7.3.5.3.Germany market size and forecast, by application
7.3.5.4.Germany market size and forecast, by end user
7.3.5.5.France
7.3.5.6.France market size and forecast, by Treatment
7.3.5.7.France market size and forecast, by application
7.3.5.8.France market size and forecast, by end user
7.3.5.9.UK
7.3.5.10.UK market size and forecast, by Treatment
7.3.5.11.UK market size and forecast, by application
7.3.5.12.UK market size and forecast, by end user
7.3.5.13.Italy
7.3.5.14.Italy market size and forecast, by Treatment
7.3.5.15.Italy market size and forecast, by application
7.3.5.16.Italy market size and forecast, by end user
7.3.5.17.Spain
7.3.5.18.Spain market size and forecast, by Treatment
7.3.5.19.Spain market size and forecast, by application
7.3.5.20.Spain market size and forecast, by end user
7.3.5.21.Rest of Europe
7.3.5.22.Rest of Europe market size and forecast, by Treatment
7.3.5.23.Rest of Europe market size and forecast, by application
7.3.5.24.Rest of Europe market size and forecast, by end user
7.4.Asia-Pacific
7.4.1.Key trends and growth opportunities
7.4.2.Market size and forecast, by Treatment
7.4.3.Market size and forecast, by application
7.4.4.Market size and forecast, by end user
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.2.Japan market size and forecast, by Treatment
7.4.5.3.Japan market size and forecast, by application
7.4.5.4.Japan market size and forecast, by end user
7.4.5.5.China
7.4.5.6.China market size and forecast, by Treatment
7.4.5.7.China market size and forecast, by application
7.4.5.8.China market size and forecast, by end user
7.4.5.9.India
7.4.5.10.India market size and forecast, by Treatment
7.4.5.11.India market size and forecast, by application
7.4.5.12.India market size and forecast, by end user
7.4.5.13.Australia
7.4.5.14.Australia market size and forecast, by Treatment
7.4.5.15.Australia market size and forecast, by application
7.4.5.16.Australia market size and forecast, by end user
7.4.5.17.South Korea
7.4.5.18.South Korea market size and forecast, by Treatment
7.4.5.19.South Korea market size and forecast, by application
7.4.5.20.South Korea market size and forecast, by end user
7.4.5.21.Rest of Asia-Pacific
7.4.5.22.Rest of Asia-Pacific market size and forecast, by Treatment
7.4.5.23.Rest of Asia-Pacific market size and forecast, by application
7.4.5.24.Rest of Asia-Pacific market size and forecast, by end user
7.5.LAMEA
7.5.1.Key trends and opportunities
7.5.2.Market size and forecast, by Treatment
7.5.3.Market size and forecast, by application
7.5.4.Market size and forecast, by end user
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.2.Brazil market size and forecast, by Treatment
7.5.5.3.Brazil market size and forecast, by application
7.5.5.4.Brazil market size and forecast, by end user
7.5.5.5.Saudi Arabia
7.5.5.6.Saudi Arabia market size and forecast, by Treatment
7.5.5.7.Saudi Arabia market size and forecast, by application
7.5.5.8.Saudi Arabia market size and forecast, by end user
7.5.5.9.South Africa
7.5.5.10.South Africa market size and forecast, by Treatment
7.5.5.11.South Africa market size and forecast, by application
7.5.5.12.South Africa market size and forecast, by end user
7.5.5.13.Rest of LAMEA
7.5.5.14.Rest of LAMEA market size and forecast, by Treatment
7.5.5.15.Rest of LAMEA market size and forecast, by application
7.5.5.16.Rest of LAMEA market size and forecast, by end user
CHAPTER 8:COMPANY PROFILES
8.1.Alimera Sciences Inc.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.Abbvie Inc.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.Bausch Health Companies Inc.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.Bayer AG
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.F. Hoffmann-La Roche Ltd
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.4 Business performance
8.5.5.Key strategic moves and developments
8.6.GlaxoSmithKline Plc
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.Kubota Pharmaceutical Hodlings Co. Ltd.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Key strategic moves and developments
8.8.Novartis AG
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.Regeneron Pharmaceuticals Inc.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.Regen X Bio Inc.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
8.10.4.Business performance
8.10.5.Key strategic moves and developments
LIST OF TABLES
TABLE 01.MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2020–2030($MILLION)
TABLE 02.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR DRUG THERAPY, BY REGION, 2020–2030($MILLION)
TABLE 03.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR LASER TREATMENT, BY REGION, 2020–2030 ($MILLION)
TABLE 04.MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 05.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR MACULAR EDEMA, BY REGION, 2020–2030 ($MILLION)
TABLE 06.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR MACULAR DEGENERATION, BY REGION, 2020–2030 ($MILLION)
TABLE 07.MACULAR EDEMA AND MACULAR DEGENERATIONMARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 08.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR HOSPITALS, BY REGION, 2020–2030 ($MILLION)
TABLE 09.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR CLINICS, BY REGION, 2020–2030 ($MILLION)
TABLE 10.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 11.MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 12.NORTH AMERICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 13.NORTH AMERICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 14.NORTH AMERICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 15.NORTH AMERICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 16.U.S. MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 17.U.S. MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 18.U.S. MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 19.CANADA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 20.CANADA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 21.CANADA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 22.MEXICO MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 23.MEXICO MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 24.MEXICO MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 25.EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 26.EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 27.EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 28.EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 29.GERMANY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 30.GERMANY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 31.GERMANY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 32.FRANCE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 33.FRANCE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 34.FRANCE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 35.UK MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 36.UK MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 37.UK MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 38.ITALY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 39.ITALY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 40.ITALY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 41.SPAIN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 42.SPAIN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 43.SPAIN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 44.REST OF EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 45.REST OF EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 46.REST OF EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 47.ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 48.ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 49.ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 50.ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 51.JAPAN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 52.JAPAN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 53.JAPAN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 54.CHINA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 55.CHINA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 56.CHINA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 57.INDIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 58.INDIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 59.INDIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 60.AUSTRALIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 61.AUSTRALIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 62.AUSTRALIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 63.SOUTH KOREA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 64.SOUTH KOREA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 65.SOUTH KOREA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 66.REST OF ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 67.REST OF ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 68.REST OF ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 69.LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 70.LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 71.LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 72.LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 73.BRAZIL MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 74.BRAZIL MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 75.BRAZIL MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 76.SAUDI ARABIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 77.SAUDI ARABIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 78.SAUDI ARABIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 79.SOUTH AFRICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 80.SOUTH AFRICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 81.SOUTH AFRICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 82.REST OF LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 83.REST OF LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 84.REST OF LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 85.ALIMERA SCIENCES: COMPANY SNAPSHOT
TABLE 86.ALIMERA SCIENCES: OPERATING SEGMENTS
TABLE 87.ALIMERA SCIENCES: PRODUCT PORTFOLIO
TABLE 88.ALIMERA SCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 89.ABBVIE: COMPANY SNAPSHOT
TABLE 90.ABBVIE: OPERATING SEGMENTS
TABLE 91.ABBVIE: PRODUCT PORTFOLIO
TABLE 92.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 93.BAUSCH HEALTH: COMPANY SNAPSHOT
TABLE 94.BAUSCH HEALTH: OPERATING SEGMENTS
TABLE 95.BASUCH HEALTH: PRODUCT PORTFOLIO
TABLE 96.BAUSCH HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.BAYER: COMPANY SNAPSHOT
TABLE 98.BAYER: OPERATING SEGMENTS
TABLE 99.BAYER: PRODUCT PORTFOLIO
TABLE 100.BAYER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101.ROCHE: COMPANY SNAPSHOT
TABLE 102.ROCHE: OPERATING SEGMENTS
TABLE 103.ROCHE: PRODUCT PORTFOLIO
TABLE 104.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105.GSK : PRODUCT PORTFOLIO
TABLE 106.GSK: OPERATING SEGMENTS
TABLE 107.GSK : PRODUCT PORTFOLIO
TABLE 108.KUBOTA: COMPANY SNAPSHOT
TABLE 109.KUBOTA: OPERATING SEGMENTS
TABLE 110.KUBOTA: PRODUCT PORTFOLIO
TABLE 111.KUBOTA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112.NOVARTIS : OPERATING SEGMENTS
TABLE 113.NOVARTIS : PRODUCT PROTFOLIO
TABLE 114.NOVARTIS: KEY STRAGIC MOVES AND DEVELOPMENTS
TABLE 115.REGENERON: COMPANY SNAPSHOT
TABLE 116.REGENERON: OPERATING SEGMENTS
TABLE 117.REGENERON: PRODUCT PORTFOLIO
TABLE 118.REGENERON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 119.REGEN X BIO: COMPANY SNAPSHOT
TABLE 120.REGEN X BIO: PRODUCT PORTFOLIO
TABLE 121.REGEN X BIO : KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 01.TOP INVESTMENT POCKETS
FIGURE 02.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 03.MODERATE BARGAINING POWER OF BUYERS
FIGURE 04.MODERATE THREAT OF SUBSTITUTES
FIGURE 05.MODERATE THREAT OF NEW ENTRANTS
FIGURE 06.HIGH INTENSITY OF RIVALRY
FIGURE 07.TOP PLAYER POSITIONING, 2020
FIGURE 08.COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR DRUG THERAPY BY COUNTRY, 2020 & 2030 (%)
FIGURE 09.COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR LASER TREATMENT BY COUNTRY, 2020 & 2030 (%)
FIGURE 10.COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR MACULAR EDEMA BY COUNTRY, 2020 & 2030 (%)
FIGURE 11.COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR MACULAR DEGENERATION BY COUNTRY, 2020 & 2030 (%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR HOSPITALS BY COUNTRY, 2020 & 2030 (%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR CLINICS BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR OTHERS BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.ALIMERA SCIENCES: NET SALES, 2018–2020 ($MILLION)
FIGURE 16.ALIMERA SCIENCES:REVENUE SHARE BY REGION, 2020 (%)
FIGURE 17.ABBVIE: NET SALES 2020 (%)
FIGURE 18.ABBVIE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 19.BAUSCH HEALTH: NET SALES, 2018–2020 ($MILLION)
FIGURE 20.BAUSCH HEALTH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 21.BAUSCH HEALTH: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 22.BAYER: NET SALES, 2018–2020 ($MILLION)
FIGURE 23.BAYER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 24.BAYER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 25.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 28.GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.GSK: REVENUE SHARE BY SEGMENT, 2018–2020 ($MILLION)
FIGURE 30.GSK: REVENUE SHARE BY REGION, 2018–2020 ($MILLION)
FIGURE 31.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 33.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 34.REGENERON: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.REGENERON: REVENUE SHARE BY SEGMENT, 2020 (%)
Increase in aging population, which leads to increase in number of macular edema and degeneration cases. In addition, the disease poses greater risk among adults aged between 40 and 80, thus it can be associated with age related syndromes such as macular degeneration, vascular diseases, and obstructive sleep apnea. However, surge in geriatric population, growth in pipeline of AMD therapeutics, increase in prevalence of chronic diseases, and rise in healthcare expenditure are some prominent factors that drive the market growth. Moreover, high cost involved and limited awareness in developing countries hinder growth of the global macular degeneration market.
Therapies such as anti-vascular endothelial growth factor drugs for treatment of diabetic macular edema and Lucentis (ranibizymab) & Avastin drugs for macular degeneration play a significant role in growth of global macular edema and degeneration market. In addition, key players in this industry have focused on expanding their presence in emerging economies, which is anticipated to drive the market growth.
A. The total market value of Macular Edema and Macular Degeneration Market is $16,530 Million in 2030
A. The forecast period in the report is from 2021 to 2030
A. The market value of Macular Edema and Macular Degeneration Market in 2020 was $8,301 million
A. The base year for the report is 2020
A. Yes, Macular Edema and Macular Degeneration Market companies are profiled in the report
A. The top companies that hold the market share in Macular Edema and Macular Degeneration Market are F. Hoffmann-La Roche Ltd, Abbvie Inc., Bausch Health Companies Inc., Bayer AG, GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc., and Novartis AG
A. No, there is no value chain analysis provided in the Macular Edema and Macular Degeneration Market report
A. The key trends in the Macular Edema and Macular Degeneration Market are the increasing burden of retinal disorders, upsurge in the geriatric population, and rise in occurrence of diabetes due to unhealthy lifestyle of people and increasing cases of diabetes.
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
